Please assess the completion status of the following clinical trial:

Trial Title: Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with moderate to severe chronic low back pain (lasting several hours daily) as their predominant pain condition for at least 3 months prior to screening,~* Subjects treated within the 14 days prior to screening with nonopioid therapy only, or with therapy including opioids at a dose of \<5 mg oxycodone (or equivalent) per day,~* Subjects whose low back pain is not adequately controlled with non-opioid analgesic medication and who the Investigator feels are appropriate candidates for around-the-clock opioid therapy~Exclusion Criteria:~* Subjects who had a surgical procedure directed towards the source of back pain within 6 months of screening or planned during the study conduct period,~* Subjects who are allergic to buprenorphine or who had a history of allergies to other opioids,~* Subjects who have allergies or other contraindications to transdermal delivery systems or patch adhesives.~Other protocol-specific inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Double-blind BTDS 10 or 20 (Type: EXPERIMENTAL): Buprenorphine transdermal system 10 or 20 mcg/h applied for 7-day wear
- Double-blind Placebo TDS (Type: PLACEBO_COMPARATOR): Placebo transdermal system to match BTDS patches, applied for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).